Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant injection for prevention of postoperative nausea and vomiting (real-world study)
ChiCTR2400094420Phase 2Recruiting
- Sponsor
- Chongqing Changshou District People's Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aprepitant in postoperative nausea and vomiting (PONV), sponsored by Chongqing Changshou District People's Hospital. Primary endpoint: 24-hour complete response after surgery. Started Dec 2024; status: recruiting.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2400094420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094420.